Ashwagandha is not a drug in the United States. It is legally classified as a dietary supplement, which places it in a special category under foods, not pharmaceuticals. That said, ashwagandha contains compounds that act on the brain and hormonal system in ways that overlap with how some drugs work, which is why the question comes up so often.
How the Law Classifies Ashwagandha
Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, Congress created a distinct legal category for products containing herbs, vitamins, minerals, and other botanical ingredients. Ashwagandha falls squarely into this category as an herbal supplement. The practical difference between a supplement and a drug comes down to one word: approval. Drugs must be proven safe and effective before they can be sold. Dietary supplements do not need FDA approval before reaching store shelves. Manufacturers are responsible for evaluating the safety of their own products.
This distinction also controls what companies can say on the label. A dietary supplement can describe how an ingredient affects the body’s structure or function, like “supports relaxation” or “promotes healthy stress response.” It cannot claim to diagnose, treat, cure, or prevent any disease. If a supplement makes that kind of disease claim, it legally becomes a drug and is subject to drug regulations. Every ashwagandha product sold as a supplement must carry a disclaimer stating it has not been evaluated by the FDA and is not intended to treat any disease.
The FDA does recognize a separate pathway for “botanical drug products,” which are plant-derived substances intended for use in treating or preventing disease. These go through clinical trials and a formal approval process, just like synthetic drugs. Ashwagandha has not gone through this process and is not approved as a botanical drug.
Why It Acts Like One in the Body
The reason people wonder whether ashwagandha is a drug is that its active compounds, called withanolides, interact with the body in measurable, pharmacologically significant ways. These aren’t vague or theoretical effects. Withanolides bind directly to GABA receptors in the brain, the same receptors targeted by prescription sedatives and anti-anxiety medications. When researchers block those receptors with antagonist chemicals, ashwagandha’s sleep-promoting effects disappear, confirming that the binding is responsible for the calming effect.
Ashwagandha also influences the body’s stress hormone system. One of its key compounds, Withaferin A, appears to interact directly with glucocorticoid receptors in the brain, which regulate cortisol production. In a 60-day randomized, double-blind trial using a standardized root extract (KSM-66), participants taking ashwagandha saw their cortisol levels drop by 27.9% from baseline, compared to just 7.9% in the placebo group. That is a substantial hormonal shift from an over-the-counter supplement.
Beyond the brain and stress hormones, ashwagandha reduces markers of inflammation and restores key antioxidant enzymes in cells exposed to oxidative stress. In human studies, supplementation lowered levels of a protein called Nuclear Factor Kappa B, a central driver of inflammatory processes throughout the body. None of this means ashwagandha is “just an herb” with negligible effects. It has real biological activity, which is exactly why it also carries real risks.
Doses Used in Research
Clinical trials have used ashwagandha at doses ranging from 240 to 1,250 mg per day of standardized extract. The most commonly studied form, KSM-66, is typically dosed at 600 mg per day (two 300 mg capsules), standardized to contain at least 5% withanolides. Another extract called Shoden uses a lower volume but a higher concentration, delivering about 42 mg of withanolide glycosides per day across two capsules.
An international task force created by the World Federation of Societies of Biological Psychiatry and the Canadian Network for Mood and Anxiety Treatments has provisionally recommended 300 to 600 mg per day of root extract (standardized to 5% withanolides) for generalized anxiety. “Provisionally” is the key word: this is a conditional recommendation, not a firm clinical guideline on par with established pharmaceuticals.
Known Safety Risks
Because ashwagandha is sold as a supplement, it doesn’t go through the rigorous pre-market safety testing that drugs do. Most side effect data comes from clinical trials and post-market case reports rather than the large safety databases that exist for prescription medications.
The most serious documented risk is liver injury. The National Institutes of Health’s LiverTox database gives ashwagandha a “B” likelihood score, meaning it is a likely cause of clinically apparent liver damage. As of a 2024 review, 23 cases of liver injury linked to ashwagandha had been reported in the medical literature. That number is small relative to the millions of people who take it, but the injuries are not trivial. Liver damage typically appears 2 to 12 weeks after starting supplementation and presents with jaundice and itching. Rare cases have required emergency liver transplantation, particularly in people who already had liver disease or cirrhosis.
Ashwagandha’s hormonal activity also raises concerns about interactions with medications. Its effect on cortisol could theoretically amplify the effects of drugs that suppress the immune system or lower blood sugar. Its influence on thyroid hormone levels is another area of concern for people on thyroid medication. Because supplement-drug interactions are not systematically tested the way drug-drug interactions are, much of this remains based on the known pharmacology rather than large-scale interaction studies.
It’s Restricted in Some Countries
Not every country treats ashwagandha the way the U.S. does. Denmark banned it outright based on a 2020 government report concluding that its root has negative effects on sex hormones and reproduction in both men and women, and that it can affect metabolism, the immune system, and the central nervous system. That ban remains in effect.
Poland takes a middle approach: ashwagandha roots are allowed, but leaves and other plant parts are not, and products must contain less than 10 mg of withanolides per daily portion. Germany has expressed concerns, likely based on the same Danish-affiliated report, but has not pulled ashwagandha from the market. Sweden leaves regulatory decisions to local authorities rather than imposing a national ban.
These varying approaches reflect genuine scientific uncertainty. The same biological activity that makes ashwagandha appealing for stress and sleep is the same activity that makes regulators in some countries uncomfortable with it being sold without medical oversight.
Supplement vs. Drug: A Blurry Line
The honest answer to “is ashwagandha a drug?” depends on whether you mean legally or pharmacologically. Legally, in the U.S., it is a dietary supplement. It sits on the same shelf as multivitamins and fish oil. It does not require a prescription, and the FDA does not evaluate its effectiveness before it is sold.
Pharmacologically, ashwagandha acts on the same brain receptors and hormonal pathways that many prescription drugs target. It produces measurable changes in cortisol, GABA activity, and inflammatory markers at doses commonly found in commercial products. The fact that it is sold without a prescription does not mean it is biologically inert, and the fact that it is biologically active does not make it an FDA-approved drug. Both things are true at the same time, and that gap between legal status and biological potency is worth understanding before you start taking it.